Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174674 | 0.83 | MEN1 (0.70) | RAB9ASMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL7203066 | 0.82 | ERCC5 (0.56) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5591953 | 0.81 | HPGDS (0.62) | RAB9AMAPTSMN1; SMN2NPC1KMT2A | |
| SCHEMBL7059348 | 0.80 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1867503 | 0.80 | GAA (0.60) | RAB9AMAPTSMN1; SMN2NPC1TDP1 | |
| SCHEMBL1858111 | 0.80 | RAB9A (0.78) | RAB9AMAPTSMN1; SMN2NPC1TDP1 | |
| SCHEMBL15137067 | 0.77 | MEN1 (0.67) | RAB9ASMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL2529744 | 0.77 | LMNA (0.69) | RAB9AMAPTSMN1; SMN2NPC1TDP1 | |
| SCHEMBL12857778 | 0.77 | RAB9A (0.67) | RAB9AMAPTSMN1; SMN2NPC1TDP1 | |
| SCHEMBL12857660 | 0.76 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| EP-1478364-B1 | SELECTIVE ANTIBACTERIAL AGENTS | QUONOVA LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1478364-B1 | SELECTIVE ANTIBACTERIAL AGENTS | QUONOVA LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | RAB9A 4031/4885MAPT 4855/4885SMN1; SMN2 2316/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | RAB9A 4032/4885MAPT 4855/4885SMN1; SMN2 2336/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | RAB9A 4032/4885MAPT 4855/4885SMN1; SMN2 2336/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | RAB9A 4013/4885MAPT 4856/4885SMN1; SMN2 2331/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | RAB9A 3999/4885MAPT 4857/4885SMN1; SMN2 2207/4885 |
| US-20040063765-A1 | Modulation of pathogenicity | NR1H4, NR4A1, MSR1 | RAB9A 3056/4885MAPT 4848/4885SMN1; SMN2 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.